AR and prostate cancer: For instance, the rhythmic transport of DCs to tumor-draining lymph nodes controls the CD80-dependent circadian response of specific CD8+ T cells, thus synchronous immune therapy with DC function yields better efficacy.121 However, in prostate cancer (PCa), resistance to androgen receptor (AR)-targeted therapy is also linked to circadian rhythm.